MHLW Panel to Review Kyorin’s OAB Drug Vibegron and More on Aug. 30

Kyorin Pharmaceutical’s overactive bladder (OAB) treatment vibegron, licensed from US Merck, will come up for review by a key health ministry panel along with other medicines on August 30. If all goes well, it is expected to win an official...read more